Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit V Khera

Showing results (21-30 of 136) with videos related to

Pageof 14
Sort By:
The American Journal of Cardiology|June 30, 2015
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)Amit V Khera, Arman Qamar, Sabina A Murphy, et al.
Cardiovascular Diabetology|July 14, 2022
Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank studyJae-Seung Yun, Sang-Hyuk Jung, Manu Shivakumar, et al.
JAMA|February 15, 2017
Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart DiseaseConnor A Emdin, Amit V Khera, Pradeep Natarajan, et al.
JHEP Reports : Innovation in Hepatology|March 20, 2023
Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort studyMelanie Zheng, Daniel Q Huang, Chigoziri Konkwo, et al.
Circulation|November 19, 2013
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
The American Journal of Cardiology|April 13, 2010
Accuracy of noninvasively determined pulmonary artery systolic pressureJeffrey M Testani, Martin G St John Sutton, Susan E Wiegers, et al.
NPJ Digital Medicine|July 27, 2022
Silhouette images enable estimation of body fat distribution and associated cardiometabolic riskMarcus D R Klarqvist, Saaket Agrawal, Nathaniel Diamant, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetesLana Bridi, Saaket Agrawal, Kaleb Tesfai, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 29, 2020
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National BiobankAniruddh P Patel, Minxian Wang (汪敏先), James P Pirruccello, et al.
Frontiers in Cardiovascular Medicine|September 5, 2022
Associations between polygenic risk of coronary artery disease and type 2 diabetes, lifestyle, and cardiovascular mortality: A prospective UK Biobank studyJae-Seung Yun, Sang-Hyuk Jung, Manu Shivakumar, et al.
Pageof 14

Showing results (21-30 of 136) with videos related to

Sort By:
Pageof 14
The American Journal of Cardiology|June 30, 2015
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)Amit V Khera, Arman Qamar, Sabina A Murphy, et al.
Cardiovascular Diabetology|July 14, 2022
Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank studyJae-Seung Yun, Sang-Hyuk Jung, Manu Shivakumar, et al.
JAMA|February 15, 2017
Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart DiseaseConnor A Emdin, Amit V Khera, Pradeep Natarajan, et al.
JHEP Reports : Innovation in Hepatology|March 20, 2023
Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort studyMelanie Zheng, Daniel Q Huang, Chigoziri Konkwo, et al.
Circulation|November 19, 2013
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)Amit V Khera, Brendan M Everett, Michael P Caulfield, et al.
The American Journal of Cardiology|April 13, 2010
Accuracy of noninvasively determined pulmonary artery systolic pressureJeffrey M Testani, Martin G St John Sutton, Susan E Wiegers, et al.
NPJ Digital Medicine|July 27, 2022
Silhouette images enable estimation of body fat distribution and associated cardiometabolic riskMarcus D R Klarqvist, Saaket Agrawal, Nathaniel Diamant, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetesLana Bridi, Saaket Agrawal, Kaleb Tesfai, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 29, 2020
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National BiobankAniruddh P Patel, Minxian Wang (汪敏先), James P Pirruccello, et al.
Frontiers in Cardiovascular Medicine|September 5, 2022
Associations between polygenic risk of coronary artery disease and type 2 diabetes, lifestyle, and cardiovascular mortality: A prospective UK Biobank studyJae-Seung Yun, Sang-Hyuk Jung, Manu Shivakumar, et al.
Pageof 14